Advertisement

Topics

FDA Lifts Clinical Hold on Epizyme’s Tazemetostat Program in Follicular Lymphoma

10:50 EDT 25 Sep 2018 | Speciality Pharma Journal

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold that had paused U.S.-based enrollment of new patients in its tazemetostat clinical trials. Epizyme is now in the process of reopening enrollment in all of its company-sponsored …

Original Article: FDA Lifts Clinical Hold on Epizyme’s Tazemetostat Program in Follicular Lymphoma

NEXT ARTICLE

More From BioPortfolio on "FDA Lifts Clinical Hold on Epizyme’s Tazemetostat Program in Follicular Lymphoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Epigenetics
The development and maintenance of an organism is orchestrated by a set of chemical reactions that switch parts of the genome off and on at strategic times and locations. Epigenetics is the study of these reactions and the factors that influence them. ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...